Soluble and Cell-based Markers of Immune Checkpoint Inhibitor-associated Nephritis
Overview
Oncology
Pharmacology
Authors
Affiliations
Background: Non-invasive biomarkers of immune checkpoint inhibitor-associated acute tubulointerstitial nephritis (ICI-nephritis) are urgently needed. Because ICIs block immune checkpoint pathways that include cytotoxic T lymphocyte antigen 4 (CTLA4), we hypothesized that biomarkers of immune dysregulationpreviously defined in patients with congenital CTLA4 deficiency, including elevated soluble interleukin-2 receptor alpha (sIL-2R) and flow cytometric cell-based markers of B and T cell dysregulation in peripheral blood may aid the diagnosis of ICI-nephritis.
Methods: A retrospective cohort of patients diagnosed with ICI-nephritis was compared with three prospectively enrolled control cohorts: ICI-treated controls without immune-related adverse events, patients not on ICIs with hemodynamic acute kidney injury (hemodynamic AKI), and patients not on ICIs with biopsy proven acute interstitial nephritis from other causes (non-ICI-nephritis). sIL-2R level and flow cytometric parameters were compared between groups using Wilcoxon rank sum test or Kruskal-Wallis test. Receiver operating characteristic curves were generated to define the accuracy of sIL-2R and flow cytometric biomarkers in diagnosing ICI-nephritis. The downstream impact of T cell activation in the affected kidney was investigated using archived biopsy samples to evaluate the gene expression of IL-2 signaling, and T cell receptor signaling in patients with ICI-nephritis compared with other causes of drug-induced nephritis, acute tubular injury, and histologically normal controls.
Results: sIL-2R level in peripheral blood was significantly higher in patients with ICI-nephritis (N=24) (median 2.5-fold upper limit of normal (ULN), IQR 1.9-3.3), compared with ICI-treated controls (N=10) (median 0.8-fold ULN, IQR 0.5-0.9, p<0.001) and hemodynamic AKI controls (N=6) (median 0.9-fold-ULN, IQR 0.7-1.1, p=0.008). A sIL-2R cut-off point of 1.75-fold ULN was highly diagnostic of ICI-nephritis (area under the curve >96%) when compared with either ICI-treated or hemodynamic AKI controls. By peripheral blood flow cytometry analysis, lower absolute CD8+T cells, CD45RA+CD8+ T cells, memory CD27+B cells, and expansion of plasmablasts were prominent features of ICI-nephritis compared with ICI-treated controls. Gene expressions for , IL-2 signaling, and T cell receptor signaling in the kidney tissue with ICI-nephritis were significantly higher compared with controls.
Conclusion: Elevated sIL-2R level and flow cytometric markers of both B and T cell dysregulation may aid the diagnosis of ICI-nephritis.
Wang J, Zuo Y, Wang W, Xu J, Liu C, Jiang M Clin Exp Med. 2025; 25(1):70.
PMID: 40029438 PMC: 11876270. DOI: 10.1007/s10238-025-01557-7.
Urine proteomics defines an immune checkpoint-associated nephritis signature.
Long J, Singh S, Dong Y, Yee C, Lin J J Immunother Cancer. 2025; 13(1).
PMID: 39863302 PMC: 11784134. DOI: 10.1136/jitc-2024-010680.
Novel Biomarkers and Imaging Tests for AKI Diagnosis in Patients with Cancer.
Mistry K, Sadarangani S, Moreno D, Mejia S, Moledina D, Sise M Kidney360. 2024; .
PMID: 39575585 PMC: 11793192. DOI: 10.34067/KID.0000000660.
Gomez-Preciado F, Martinez-Valenzuela L, Anton-Pampols P, Fulladosa X, Tena M, Goma M Clin Kidney J. 2024; 17(8):sfae200.
PMID: 39131079 PMC: 11316395. DOI: 10.1093/ckj/sfae200.
Nephrotoxicity in the Age of Immune Checkpoint Inhibitors: Mechanisms, Diagnosis, and Management.
Moturi K, Sharma H, Hashemi-Sadraei N Int J Mol Sci. 2024; 25(1).
PMID: 38203586 PMC: 10778678. DOI: 10.3390/ijms25010414.